Concordance between sustained virologic response week 12 (SVR12) and SVR24 in genotype 1 hepatitis C virus patients receiving interferon-free treatment in the SOUND-C2 study

Hepatology

Volumn 58, Issue 4, 2013, Pages 1516-

  Zeuzem, Stefan ^a   Mensa, Federico J ^b  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BI 207127; DELEOBUVIR; FALDAPREVIR; MONTIRELIN; NONSTRUCTURAL PROTEIN 5B; VIRUS RNA;

ANTIVIRAL THERAPY; CLINICAL FEATURE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LETTER; LIMIT OF DETECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PREDICTIVE VALUE; PRIORITY JOURNAL; RELAPSE; TREATMENT RESPONSE;

ANTIVIRAL AGENTS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; POLYETHYLENE GLYCOLS; RIBAVIRIN; VIRAL LOAD;

EID: 84884978560     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26363     Document Type: Letter

References (4)

1. Marcellin P, Cheinquer H, Curescu M, Dusheiko GM, Ferenci P, Horban A, et al. High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials. Hepatology 2012;56:2039-2050.
2. Zeuzem S, Soriano V, Asselah T, Bronowicki JP, Lohse AW, Mullhaupt B, et al. SOUND-C2: SVR4, 12, and 24 concordance in genotype (GT) 1 HCV patients receiving interferon (IFN)-free treatment with the HCV NS3/4A protease inhibitor BI 201335 and the NS5B polymerase inhibitor BI 207127. Hepatology 2012;56(Suppl):569A.
3. Medrano J, Barreiro P, Resino S, Tuma P, Rodriguez V, Vispo E, et al. Rate and timing of Hepatitis C Virus relapse after a successful course of pegylated interferon plus ribavirin in HIV-Infected and HIV-uninfected patients. Clin Infect Dis 2009;49:1397-1401.
4. Lawitz E, Poordad F, Kowdley KV, Jensen D, Cohen, S. Siggelkow, K. et al. A 12-week interferon-free regimen of ABT-450/r, ABT-072, and ribavirin was well tolerated and achieved sustained virologic response in 91% treatment-naïve HCV IL28B-CC genotype-1-infected subjects. J Hepatol 2012;56(Suppl 2):S7.